SciSparc (SPRC) News Today $0.23 0.00 (-1.60%) (As of 12:00 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period SciSparc Ltd. Reports Changes in Financial PositionNovember 5, 2024 | markets.businessinsider.comSciSparc Ltd. Reschedules Annual General MeetingOctober 23, 2024 | markets.businessinsider.comSciSparc Ltd. Gains Shareholder Approval for ProposalsOctober 23, 2024 | markets.businessinsider.comAthersys Inc (OTC:ATHX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comSciSparc Ltd: SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome TreatmentSeptember 30, 2024 | finanznachrichten.dePharma Company Gets FDA Green Light For Next Phase Trial For Tourette SyndromeSeptember 30, 2024 | benzinga.comSciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome TreatmentSeptember 30, 2024 | globenewswire.comSciSparc Inks Non-binding LOI To Sell Its Entire Ownership Interest In MitoCareX BioSeptember 27, 2024 | markets.businessinsider.comSciSparc signs LOI to sell entire ownership in MitoCareXSeptember 26, 2024 | msn.comSciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareXSeptember 26, 2024 | globenewswire.comSciSparc Ltd: SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 24, 2024 | finanznachrichten.deSciSparc Says FDA OKs Initiation Of Phase IIb Clinical Trial For SCI-110 To Treat Tourette SyndromeSeptember 24, 2024 | markets.businessinsider.comSciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 23, 2024 | globenewswire.comSciSparc Ltd: SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 19, 2024 | finanznachrichten.deSciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 18, 2024 | globenewswire.comSciSparc Ltd. (SPRC)September 18, 2024 | finance.yahoo.comSciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination TherapySeptember 16, 2024 | globenewswire.comSciSparc Slides Following AutoMax DealSeptember 11, 2024 | msn.comSciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle ManufacturerSeptember 11, 2024 | globenewswire.comSciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentSeptember 6, 2024 | globenewswire.comSciSparc (NASDAQ:SPRC) Stock Quotes, Forecast and News SummaryAugust 30, 2024 | benzinga.comSciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based CombinationAugust 29, 2024 | globenewswire.comSciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 MillionAugust 28, 2024 | globenewswire.comSciSparc Ltd: SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette SyndromeAugust 24, 2024 | finanznachrichten.deSciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette SyndromeAugust 23, 2024 | globenewswire.comSciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory BoardAugust 22, 2024 | globenewswire.comSciSparc and Polyrizon sign global agreement for pain therapyAugust 20, 2024 | msn.comSciSparc Ltd: SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 TreatmentAugust 20, 2024 | finanznachrichten.deIsraeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain TherapyAugust 19, 2024 | msn.comSciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 TreatmentAugust 19, 2024 | globenewswire.comSciSparc Ltd: SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 millionAugust 17, 2024 | finanznachrichten.deSciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 millionAugust 16, 2024 | globenewswire.comSciSparc Ltd: SciSparc Updates Regarding the Status of the AutoMax MergerAugust 16, 2024 | finanznachrichten.deSciSparc Soars In Pre-market After Updating Merger With AutoMax MotorsAugust 15, 2024 | markets.businessinsider.comWhy Is SciSparc (SPRC) Stock Up 94% Today?August 15, 2024 | investorplace.comSciSparc Updates Regarding the Status of the AutoMax MergerAugust 14, 2024 | globenewswire.comPsychedelic drug developers face setback as ecstasy-based drug rejected by FDAAugust 9, 2024 | msn.comSciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss DrugAugust 6, 2024 | globenewswire.comSciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung CancerJuly 22, 2024 | globenewswire.comSciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 millionJuly 17, 2024 | globenewswire.comSciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price NotificationJuly 16, 2024 | globenewswire.comSciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight LossJuly 16, 2024 | globenewswire.comSciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded CompanyJuly 8, 2024 | globenewswire.comSciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded CompanyJuly 8, 2024 | globenewswire.comSciSparc Secures Strategic Advantage with Grant of European PatentMay 31, 2024 | globenewswire.comAction Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental HealthMay 21, 2024 | businesswire.comSciSparc to acquire AutoMax in strategic mergerApril 13, 2024 | investing.comSciSparc Ltd: SciSparc to Acquire AutoMaxApril 11, 2024 | finanznachrichten.deSciSparc to acquire vehicle importer AutoMaxApril 11, 2024 | msn.comSciSparc To Acquire AutoMax, A Strategic Leap Towards Industry DiversificationApril 11, 2024 | msn.com Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. SPRC Media Mentions By Week SPRC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRC News Sentiment▼0.000.47▲Average Medical News Sentiment SPRC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRC Articles This Week▼01▲SPRC Articles Average Week Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PHIO News SNOA News AYTU News ONCO News JAGX News VINC News ENSC News SNGX News EGRX News RDHL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRC Stock Alerts